R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

Executive Director, Regulatory, Medical & CDU - Medical, & CDU Solutions Partner

Full-TimeUpdated on 10/23/2026
$255k - $424.9k/yr
Expert
Bachelor's, Master's
Armonk, NY, USA+3 moreMore locations: Sleepy Hollow, NY, USA | Warren, MI, USA | Tarrytown, NY, USA
In PersonMany roles are performed on-site; confirm expectations with the recruiter and hiring manager.
IT OperationsEnterprise Applications

About the job

Requirements
  • A bachelor's degree in Computer Science, Information Systems, Business Administration, or a related field is required; a master's degree is preferred.
  • At least 15 years of progressive industry or relevant professional experience, including significant experience managing enterprise-scale regulatory, medical affairs, or clinical data technology platforms.
  • Experience in the biotechnology, pharmaceutical, or life sciences industry is strongly preferred.
  • Proven experience leading a multidisciplinary team of Directors and Managers, including budget and vendor contract accountability for a major function.
  • Deep expertise in regulatory information management and medical affairs systems, such as Veeva RIM, Veeva Vault, and medical inquiry/response platforms.
  • Experience with clinical data and precision medicine technology, such as clinical imaging and digital medicine platforms.
  • Strong knowledge of GxP validation practices and solution delivery life cycle management.
  • Experience managing technology capability identification, selection, and implementation across multiple simultaneous platform initiatives.
  • Proven track record of budget and vendor management for a department or major function.
  • Strong stakeholder management and negotiation skills, with experience influencing senior management internally and externally.
  • Demonstrated ability to grow, motivate, and develop teams, coaching Directors and Managers through career milestones and progression.
  • Ability to define organizational structure and set long-term goals and objectives for a major function.
  • Executive communication skills and experience engaging senior or executive leadership on sensitive or ambiguous matters.
Responsibilities
  • Serve as the key interface between business leadership and Digital & Technology for Regulatory Affairs, Medical Affairs, and Clinical Data functions, coordinating technology capabilities to deliver business objectives across the portfolio.
  • Partner with senior Regulatory Affairs, Medical Affairs, and Clinical Development leadership to align technology and capabilities with enterprise objectives and priorities.
  • Own and prioritize the multi-year platform strategy and roadmap in partnership with the business, translating business priorities into a funded, prioritized delivery plan.
  • Own the organizational design of the Reg, Medical & CDU Business Solution function, including structure, role allocation, and resourcing across Directors and Managers assigned to the domain.
  • Establish governance frameworks, standards, and validation practices for platform delivery across teams and vendor engagements.
  • Own budget, forecast, and vendor contract accountability for the domain's platform portfolio, including software licensing and services agreements.
  • Serve as the escalation and quality-assurance point for planning, prioritization, and execution of platform initiatives led by reporting Directors.
  • Oversee product backlog, incident management, and release governance across the domain's platform portfolio, ensuring consistent reporting of delivered value against plan.
  • Coach and develop Directors and Managers, ensuring delivery commitments are met and domain capabilities mature.
  • Manage steering committee meetings, working groups, and issue and release management for upgrades to existing platforms.
  • Partner with Regulatory Affairs, Medical Affairs, and Quality organizations to ensure platforms meet validation, data integrity, and audit-readiness standards for regulatory submissions and medical information.
  • Own data classification, access, and quality standards for regulatory, medical affairs, and clinical data, ensuring compliance with global submission and reporting obligations, including FDA and EMA requirements.
  • Maintain oversight of regulatory information management, medical inquiry, and clinical data workflows to ensure platforms support timely and accurate business outcomes.
  • Partner with Enterprise IT, Enterprise Architecture, and Information Security to align platform investments with enterprise standards and security requirements.
  • Build and maintain relationships with platform vendors to clarify demands, resolve conflicts, and align technology roadmaps with business needs.
  • Represent Reg, Medical & CDU technology priorities in enterprise architecture and governance forums, ensuring alignment with enterprise-wide standards.
  • Serve as the primary point of contact for senior Regulatory Affairs, Medical Affairs, and Clinical Development leadership on matters requiring negotiation of complex or ambiguous issues.
  • Build relationships with key business leaders to clarify demands, resolve conflicts, and align technology roadmaps with regulatory and medical affairs priorities.
  • Monitor industry trends in regulatory information management, medical affairs technology, and clinical data platforms, bringing innovative approaches to senior leadership.
  • Prepare and deliver executive-level materials on platform portfolio health and roadmap for governance forums and senior leadership.
Desired Qualifications
  • PMP or equivalent project/program management certification.
  • ITIL or SAFe Agile certification.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Wellness Program
  • Paid Vacation
  • Equity Awards
  • Annual Bonuses
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

10%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 21st, 2026
Regeneron trades at 19.2x earnings versus Amgen's 27.1x despite similar growth

Regeneron Pharmaceuticals trades at 19.2 times earnings for the four quarters ended June 30, 2026, well below Amgen's 27.1, though both grew revenue at a similar pace. Regeneron's revenue rose 9.3% against Amgen's 9.1%. Amgen has the higher operating margin, at 30.0% against 26.9%. Its shares also gained more over the past year, rising 51.0% against 40.4%. Regeneron's largest drug, EYLEA, is shrinking. Its revenue fell to $2.75 billion in fiscal 2025 from $4.77 billion, and management expects demand to fall further as biosimilars launch. Partners supply about half of revenue, and management expects Sanofi collaboration revenue to rise from fiscal Q3 2026. The next report is expected on or around October 30, 2026.

Yahoo Finance
Oct 19th, 2026
Regeneron's weight loss drugs could challenge Eli Lilly and Novo with 19% weight loss

Regeneron Pharmaceuticals could carve out a place in the fast-growing weight loss market, where Eli Lilly and Novo are expected to stay ahead for about five years. Its drug olatorepatide, licensed from a China-based company, mimics the GLP-1 and GIP hormones, as Lilly's Zepbound does. In a Phase 3 study in China, it led to mean weight loss of up to 19% over 48 weeks, with fewer stomach-related side effects than some rivals. Regeneron still needs US late-stage trials before approval. Its other candidate, trevogrumab, helps patients keep lean mass. In a Phase 2 study alongside Novo's semaglutide, lean mass preservation reached up to 42.5%, against 7.3% with semaglutide plus placebo. Second-quarter revenue rose 17% year over year to $4.3 billion, driven by eczema drug Dupixent.

Yahoo Finance
Oct 14th, 2026
Regeneron's Sanofi repayment ends, setting up a possible revenue boost after $2.2B record quarter

Regeneron Pharmaceuticals may get its next boost from an old deal rather than a new drug. The company finished repaying a balance to its partner Sanofi, and since the third quarter of 2026 it has recorded its full share of profits from their collaboration. Regeneron expects Sanofi collaboration revenue to step up as a result, though that remains a forecast. The repayment cut reported revenue by about $930 million in 2025 and $530 million in the first half of 2026. Revenue from the collaboration already hit a record $2.2 billion in the second quarter. A step-up matching the 2025 loss would add about 6.5% to the company's 2025 revenue of $14.3 billion. Dupixent sales reached $6 billion worldwide in the quarter, up 38% at constant currency, but growth should moderate in the second half.

Asianet News
Oct 13th, 2026
Regeneron's rare disease drug shows zero new abnormal bone growth in extended trial - REGN stock heads for best day in over A month.

Regeneron's rare disease drug shows zero new abnormal bone growth in extended trial - REGN stock heads for best day in over A month. Published: Oct 13 2026, 12:15 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us The firm's Pasatru drug was approved by the FDA in August, after trial results showed at least a 90% reduction in new abnormal bone lesions after 56 weeks. * The Phase 3 Optima trial enrolled 63 adults who received Pasatru or a placebo every four weeks. * A higher dose recorded one disease flare-up, compared with 17 in the placebo group. * The findings were presented at the American Society for Bone and Mineral Research. Regeneron Pharmaceuticals (REGN) reported encouraging long-term results for its recently approved rare disease drug on Monday, with patients showing no new abnormal bone growth during an extended Phase 3 trial. REGN shares were up about 2.8% and heading for their best day in over a month. What did the trial show? Regeneron's Pasatru treats fibrodysplasia ossificans progressiva (FOP), an extremely rare condition in which muscles, tendons and other soft tissues gradually turn into bone. The Phase 3 Optima trial enrolled 63 adults who received Pasatru or a placebo every four weeks. Between weeks 56 and 84, patients taking Pasatru developed zero new abnormal bone lesions, compared with nine in the placebo group. The findings were presented at the American Society for Bone and Mineral Research (ASBMR). Regeneron plans new study for children. The FDA approved Pasatru in August, following earlier trial results showing at least a 90% reduction in new abnormal bone lesions after 56 weeks. European regulators are currently reviewing Pasatru. The drug works by blocking Activin A, a protein involved in abnormal bone formation. Regeneron plans to begin another Phase 3 study, Optima 2, involving children and adolescents later this year. REGN's pipeline includes cancer, eye disease treatments. Beyond Pasatru, Regeneron is expanding its broader drug pipeline, which includes treatments for cancer, eye diseases and inflammatory conditions. The biotech firm recently expanded its partnership with Sanofi (SNY) to develop four new long-acting antibody treatments for inflammatory diseases. Under the deal, Regeneron will receive $1 billion upfront and could earn an additional $7 billion if the treatments meet certain development, regulatory, and sales targets. The companies will share development costs and split future profits equally. The company reported about $17.8 billion in cash and marketable securities as of June 30. Separately, BofA raised its price target on Regeneron to $908 from $891 and kept a 'Buy' rating. This implies a 19% upside from current levels. Retail remains bullish on REGN. Despite the recent run, retail sentiment on Stocktwits surrounding REGN remained 'bullish' over the past 24 hours. The stock is down around 1.4% so far this year, underperforming the broader State Street SPDR S&P Biotech ETF's (XBI) roughly 25% gains. Also read: Microsoft Looks In-House To Power Its AI Ambitions - CEO Nadella Calls It 'Our Biggest Bet Yet On Our Own Silicon' For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

Yahoo Finance
Oct 12th, 2026
Regeneron's Pasatru shows zero new bone lesions in adult FOP patients at 84 weeks

Regeneron Pharmaceuticals said its drug Pasatru (garetosmab-grts) showed sustained results in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes bone to grow in muscle and connective tissue. The 84-week data from the Phase 3 OPTIMA trial were presented at the American Society for Bone and Mineral Research annual meeting. From week 56 to week 84, patients on Pasatru had no new abnormal bone lesions, against nine for placebo. New flare-ups numbered one on the 10 mg/kg dose, 14 on the 3 mg/kg dose, and 17 on placebo. The trial enrolled 63 adults. Skin and soft tissue infections rose with dose but all resolved, and no patients stopped treatment because of them. The US Food and Drug Administration recently approved Pasatru. A trial in children and adolescents is planned to begin later this year.